Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Archives of Medical Research

• Publication date

  2000-03-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0188-4409(00)00071-0PMID 10880729
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With Chronic Myelogenous Leukemia

  2000cited by this paper
• Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients

  1997cited by this paper
• Marrow transplantation for CML: the Seattle experience.

  1996cited by this paper
• Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.

  1996cited by this paper
• Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry.

  1996cited by this paper
• Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation.

  1995cited by this paper
• Marrow transplantation for chronic myeloid leukemia.

  1995cited by this paper
• Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.

  1994cited by this paper
• Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

  1994cited by this paper
• Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.

  1993cited by this paper
• Results of allogeneic bone marrow transplantation with unrelated or mismatched donors.

  1992cited by this paper
• Indications for marrow transplantation in chronic myelogenous leukemia.

  1989cited by this paper
• Regimen-related toxicity in patients undergoing bone marrow transplantation.

  1988cited by this paper
• Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect

  1988cited by this paper
• Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

  1986cited by this paper
• Bone marrow transplantation for patients with chronic myeloid leukemia.

  1986cited by this paper
• ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA

  1984cited by this paper
• Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow.

  1984cited by this paper
• Bone marrow transplantation for chronic myeloid leukemia.

  1984cited by this paper
• Allogeneic Bone‐Marrow Transplantation

  1983cited by this paper
• Chronic cutaneous graft-versus-host disease in man.

  1978cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico.

  2016influential citation
• The treatment of chronic myeloid leukemia: A single-center, 20-year experience

  2014cites this paper
• chronic myeloid leukemia Factors affecting duration of survival after onset of blastic transformation of

  2013cites this paper
• Overall survival of chronic myeloid leukemia patients treated with related donor hematopoietic stem cell transplant or imatinib.

  2011cites this paper
• Leucemia mieloide crônica e outras doenças mieloproliferativas crônicas

  2010cites this paper
• [Chronic myeloid leukemia in the 21st century: biology and treatment].

  2009cites this paper
• Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations

  2008cites this paper
• Trasplante de células progenitoras hematopoyéticas en México

  2006cites this paper
• Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?

  2006cites this paper
• Historia del trasplante de médula

  2005cites this paper
• Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.

  2004cites this paper
• Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3+ and CD4+ lymphocytes

  2004cites this paper
• Optimizing treatment of chronic myeloid leukemia: a rational approach.

  2004cites this paper
• Hematopoietic stem cell transplantation for patients with chronic myeloid leukemia

  2004cites this paper
• Prognostic factors in chronic myeloid leukemia: allografting.

  2003cites this paper
• Allogeneic stem cell transplantation for chronic myeloid leukemia.

  2003cites this paper
• Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

  2003cites this paper
• Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes.

  2003cites this paper
• Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) Immediately After Intensive Cytoreduction for High-Risk Myeloid Leukemias

  2003cites this paper
• Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation.

  2002cites this paper
• Allogeneic peripheral blood stem cell transplantation. Safety, hematologic recovery, kinetics, and complications.

  2002cites this paper
• Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

  2002cites this paper
• Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis

  2001cites this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cites this paper
• Associations between coping and survival time of adult leukemia patients receiving allogeneic bone marrow transplantation: results of a prospective study.

  2001cites this paper
• Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia‐free survival curve

  2000cites this paper
• Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement

  1999cites this paper
• Relapse in Chronic Myeloid Leukemia after Bone Marrow Transplantation: Biomathematical Modeling as a New Approach to Understanding Pathogenesis

  1999cites this paper
• Emergence of the haematopoietic system in the human embryo and foetus.

  1999cites this paper